JP2014516977A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516977A5 JP2014516977A5 JP2014513133A JP2014513133A JP2014516977A5 JP 2014516977 A5 JP2014516977 A5 JP 2014516977A5 JP 2014513133 A JP2014513133 A JP 2014513133A JP 2014513133 A JP2014513133 A JP 2014513133A JP 2014516977 A5 JP2014516977 A5 JP 2014516977A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- nucleic acid
- acid molecule
- cancer
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 230000000259 anti-tumor effect Effects 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 238000010438 heat treatment Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 206010020843 Hyperthermia Diseases 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000012202 endocytosis Effects 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 230000036031 hyperthermia Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000002628 peritoneum cancer Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000007669 thermal treatment Methods 0.000 claims 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 1
- 108010051479 Bombesin Proteins 0.000 claims 1
- 102000013585 Bombesin Human genes 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 239000004971 Cross linker Substances 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 239000012624 DNA alkylating agent Substances 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 230000008081 blood perfusion Effects 0.000 claims 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960003677 chloroquine Drugs 0.000 claims 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 1
- 229940107161 cholesterol Drugs 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 230000000021 endosomolytic effect Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002634 lipophilic molecules Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000002071 nanotube Substances 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 150000004713 phosphodiesters Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
- 0 CCCOCC*CCOCCC*(C(O[C@]1CC2=CCC(C3C(C)(CC4)C(CCCCC(C)C)CC3)C4[C@]2(C)CC1)=O)=C Chemical compound CCCOCC*CCOCCC*(C(O[C@]1CC2=CCC(C3C(C)(CC4)C(CCCCC(C)C)CC3)C4[C@]2(C)CC1)=O)=C 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305650.1 | 2011-05-27 | ||
| EP11305650A EP2527440A1 (en) | 2011-05-27 | 2011-05-27 | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
| PCT/EP2012/059799 WO2012163814A1 (en) | 2011-05-27 | 2012-05-25 | Cancer treatment by combining dna molecules mimicking double strand breaks with hyperthermia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516977A JP2014516977A (ja) | 2014-07-17 |
| JP2014516977A5 true JP2014516977A5 (enExample) | 2015-07-02 |
| JP6162691B2 JP6162691B2 (ja) | 2017-07-12 |
Family
ID=46148891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513133A Expired - Fee Related JP6162691B2 (ja) | 2011-05-27 | 2012-05-25 | 二本鎖切断を模倣するｄｎａ分子と温熱療法との組み合わせによるガンの処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9205101B2 (enExample) |
| EP (2) | EP2527440A1 (enExample) |
| JP (1) | JP6162691B2 (enExample) |
| CN (1) | CN103732746B (enExample) |
| AU (1) | AU2012264899B2 (enExample) |
| CA (1) | CA2834194A1 (enExample) |
| EA (1) | EA023793B1 (enExample) |
| IL (1) | IL228943A (enExample) |
| WO (1) | WO2012163814A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3372248T3 (da) * | 2010-06-22 | 2020-04-06 | Onxeo | Optimeret in vivo leveringssystem med endosomolytiske midler til nukleinsyrekonjugater |
| US9663784B2 (en) | 2012-05-26 | 2017-05-30 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
| CN105899663B (zh) | 2013-12-26 | 2019-07-26 | 学校法人东京医科大学 | 用于基因表达控制的人工模拟miRNA及其用途 |
| CN106068324B (zh) | 2013-12-27 | 2020-12-29 | 株式会社博纳克 | 控制基因表达的人工匹配型miRNA及其用途 |
| WO2016104775A1 (ja) | 2014-12-27 | 2016-06-30 | 株式会社ボナック | 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途 |
| JP6602847B2 (ja) | 2015-03-27 | 2019-11-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
| LT3325623T (lt) * | 2015-07-23 | 2019-10-25 | Inst Curie | Dbait molekulės ir parp inhibitorių derinio panaudojimas vėžiui gydyti |
| WO2017148976A1 (en) * | 2016-03-01 | 2017-09-08 | Onxeo | Treatment of cancer by systemic administration of dbait molecules |
| JP7107503B2 (ja) * | 2016-12-01 | 2022-07-27 | 国立大学法人埼玉大学 | 薬物送達系用エンドサイトーシス増強剤 |
| IL282838B2 (en) * | 2018-12-21 | 2025-05-01 | Valerio Therapeutics | Conjugated nucleic acid molecules and their uses |
| KR20210142154A (ko) * | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2079109A1 (en) * | 1990-03-29 | 1991-09-30 | John A. Latham | Oligonucleotide-transport agent disulfide conjugates |
| NZ288223A (en) | 1994-06-17 | 1997-11-24 | Hoffmann La Roche | N,n'-bis(quinolin-4-yl)-diamine derivatives; antimalarial medicaments |
| AUPN741696A0 (en) * | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
| BR9813202B1 (pt) * | 1997-09-15 | 2011-11-01 | complexo de administração de genes; processo de transdução de células com material genético estranho, composição útil para administração de material genético e uso de um complexo de administração de genes. | |
| CA2337690C (en) * | 1998-07-27 | 2013-10-01 | Texas Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| EP1389209B1 (en) | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| US7476729B2 (en) | 2003-10-24 | 2009-01-13 | Institut Curie | Dbait and uses thereof |
| EP1526177A1 (en) | 2003-10-24 | 2005-04-27 | Institut Curie | Nucleic acids useful for triggering tumor cell lethality |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| WO2007040469A2 (en) | 2005-09-15 | 2007-04-12 | Kosak Ken M | Chloroquine coupled compositions and methods for their synthesis |
| US20070293449A1 (en) | 2006-06-20 | 2007-12-20 | Nastech Pharmaceutical Company Inc. | Compositions and methods for delivery of double-stranded rna |
| WO2008022309A2 (en) | 2006-08-18 | 2008-02-21 | F. Hoffmann-La Roche Ag | Polyconjugates for in vivo delivery of polynucleotides |
| EP1944369A1 (en) | 2007-01-12 | 2008-07-16 | The Centre National de la Recherche Scientifique | Dbait and its standalone uses thereof |
| JPWO2009063998A1 (ja) * | 2007-11-14 | 2011-03-31 | 株式会社リボミック | 疎水性物質付加核酸及びその使用 |
| US8575123B2 (en) | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| WO2010053489A1 (en) | 2008-11-07 | 2010-05-14 | Children's Hospital Medical Center | Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems |
| CA2742689A1 (en) * | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Branched cationic lipids for nucleic acids delivery system |
| EP2355799A4 (en) | 2008-11-17 | 2012-09-05 | Enzon Pharmaceuticals Inc | CLEANABLE FUSOGENIC LIPIDS FOR NUCLEIC ACID RELIEF SYSTEMS |
| WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
| DK3372248T3 (da) * | 2010-06-22 | 2020-04-06 | Onxeo | Optimeret in vivo leveringssystem med endosomolytiske midler til nukleinsyrekonjugater |
-
2011
- 2011-05-27 EP EP11305650A patent/EP2527440A1/en not_active Withdrawn
-
2012
- 2012-05-25 EP EP12723213.0A patent/EP2714905B1/en not_active Not-in-force
- 2012-05-25 AU AU2012264899A patent/AU2012264899B2/en not_active Ceased
- 2012-05-25 EA EA201301336A patent/EA023793B1/ru not_active IP Right Cessation
- 2012-05-25 US US14/118,583 patent/US9205101B2/en not_active Expired - Fee Related
- 2012-05-25 CA CA2834194A patent/CA2834194A1/en not_active Abandoned
- 2012-05-25 JP JP2014513133A patent/JP6162691B2/ja not_active Expired - Fee Related
- 2012-05-25 WO PCT/EP2012/059799 patent/WO2012163814A1/en not_active Ceased
- 2012-05-25 CN CN201280025978.2A patent/CN103732746B/zh not_active Expired - Fee Related
-
2013
- 2013-10-17 IL IL228943A patent/IL228943A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516977A5 (enExample) | ||
| JP7459168B2 (ja) | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 | |
| US11591596B2 (en) | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | |
| JP2019507763A5 (enExample) | ||
| Dorer et al. | Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis | |
| US11242533B2 (en) | RNA-nanostructured double robots and methods of use thereof | |
| JP2018536689A5 (enExample) | ||
| JP2019506862A5 (enExample) | ||
| JP6359028B2 (ja) | テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー | |
| JP2016535009A5 (enExample) | ||
| SI3135301T1 (en) | OPTIMIZED SYSTEM OF DELIVERY AND VIVO WITH ENDOSOMOLITIC MEANS FOR KONJUGATE NUCLEIC ACIDS | |
| Chandler et al. | Expanding structural space for immunomodulatory nucleic acid nanoparticles via spatial arrangement of their therapeutic moieties | |
| US20210246452A1 (en) | Rna nanostructures and methods of making and using rna nanostructures | |
| JP2023085547A (ja) | ｓｎｏＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 | |
| JPWO2021048799A5 (enExample) | ||
| Yaghoobi et al. | A novel targeted co-delivery system for transfer of epirubicin and antimiR-10b into cancer cells through a linear DNA nanostructure consisting of FOXM1 and AS1411 aptamers | |
| JPWO2016103531A1 (ja) | 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用 | |
| JP2014532407A5 (enExample) | ||
| Li et al. | Molecular cloning, characterization and expression of miR-15a-3p and miR-15b-3p in dairy cattle | |
| JP7048102B2 (ja) | 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用 | |
| FR2919287B1 (fr) | Nouveaux derives fluorescents de polyamines, leur procede de preparation et leurs applications en tant qu'outils de diagnostic dans le traitement des tumeurs cancereuses. | |
| CN104971361A (zh) | 一种叶酸受体靶向的敲除dnmt1基因的药物组合物 | |
| CN108472388A (zh) | 包含rna寡核苷酸的用于治疗癌症的药物组合物 | |
| CN104189919A (zh) | 针对egfr的单克隆抗体修饰的pamam自组装转基因组合物及应用 | |
| Bogadi et al. | Nucleic Acid-Based Micellar Therapy for the Treatment of Different Diseases |